ASX ANNOUNCEMENT **24 September 2026**

Notification under Listing Rule 4.3D

Melbourne, Australia; 24 September 2026: Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), advises that following the finalisation of the audit of the Group's financial accounts for the year ended 30 June 2026, a change to the results and the composition of the net liability position reported in the unaudited Appendix 4E and Preliminary Final Report lodged with the Australian Securities Exchange ("**ASX**") on 31 August 2026 was identified and will be incorporated into the audited Annual Report.

The Company had engaged a global contract research organisation ("**CRO**") to provide clinical trial management and related services for the Company's Phase 2 clinical trial of CYP-001 in acute graft-versus-host disease. The anticipated costs associated with this arrangement had previously been disclosed in the Commitments For Expenditure Note to the Group's financial statements. Following the early termination of the trial in June 2026, the Company and the CRO undertook a reconciliation of the remaining amounts payable under their agreement. Following lodgement of the Appendix 4E, the Company and the CRO reached an agreement in principle regarding the amount payable, which remains subject to formal documentation. This provided further information relevant to measuring the Company's obligation at 30 June 2026. Accordingly, the Board resolved to recognise an additional accrual in the audited financial statements solely in respect of services provided and costs incurred up to 30 June 2026. This increased research and development expenses and trade and other payables, with a corresponding increase in the Group's net liability position.

The adjustment does not include any amounts attributable to the period after 30 June 2026 and has no effect on the Group's cash balance as reported at that date. Importantly, the total amount agreed in principle with the CRO is within the forecast amount for GvHD trial close-out costs disclosed in the Company's announcement of 6 July 2026, and lower than the aggregate costs the Company would otherwise have expected to incur had the trial continued until its previously anticipated completion in late 2027.

The impact on the numbers presented is shown below:

	Appendix 4E	Audited Annual Report	Change
Loss before income tax expense	($9,089,281)	($9,248,815)	$159,534
Trade and other payables	$1,016,991	$1,176,525	$159,534

ENDS-

Authorised for release by the Board of Directors

CONTACT: investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

Cynata Therapeutics Limited
ABN – 98 104 037 372

Level 3, 100 Cubitt Street
Cremorne
VIC 3121
Australia

T: +613 7067 6940
E: info@cynata.com
www.cynata.com